Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Liabilities (2019 - 2026)

C4 Therapeutics has reported Total Liabilities over the past 8 years, most recently at $94.6 million for Q1 2026.

  • For Q1 2026, Total Liabilities fell 23.93% year-over-year to $94.6 million; the TTM value through Mar 2026 reached $94.6 million, down 23.93%, while the annual FY2025 figure was $102.5 million, 23.3% down from the prior year.
  • Total Liabilities for Q1 2026 was $94.6 million at C4 Therapeutics, down from $102.5 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $151.0 million in Q1 2022 and troughed at $94.6 million in Q1 2026.
  • A 5-year average of $129.5 million and a median of $133.6 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: skyrocketed 36.86% in 2022 and later fell 23.93% in 2026.
  • Year by year, Total Liabilities stood at $141.6 million in 2022, then fell by 7.96% to $130.3 million in 2023, then grew by 2.52% to $133.6 million in 2024, then fell by 23.3% to $102.5 million in 2025, then fell by 7.68% to $94.6 million in 2026.
  • Business Quant data shows Total Liabilities for CCCC at $94.6 million in Q1 2026, $102.5 million in Q4 2025, and $111.1 million in Q3 2025.